Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    TopAbstracts in Breast Cancer 11/18/2008 - (DGNews)
    Psychological Interventions Associated With Breast Cancer Survival - (DGNews)
    Aromatase Inhibitors, Androgen Deprivation Increase Risk of Bone Loss - (DGNews)
    TopAbstracts in Breast Cancer 11/11/2008 - (DGNews)
    Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial - (JAMA)

    News archive

     Recent webcasts/CME - Breast Cancer

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
      Granular Cell Tumour of the Pectoral Muscle Mimicking Breast Cancer
      Primary Osteosarcoma of the Breast: Case Report
      A Case of Matrix-Producing Carcinoma of the Breast
      Metastatic Hurthle Cell Carcinoma of the Thyroid Presenting as a Breast Lump: A Case Report

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Sequential Adjuvant Treatment With Docetaxel Improves Outcomes for Node Positive Breast Cancer: Presented at SABCS

      By Ed Susman

      SAN ANTONIO, TX -- December 10, 2004 -- Breast cancer patients who receive adjuvant therapy that consists of 3 treatments of fluorouracil, epirubicin, and cyclophosphamide (FEC 100) followed by 3 treatments with docetaxel fare better than those who receive 6 cycles of FEC 100.

      Principal investigator Henri Roché, MD, professor of medical oncology, Institut Claudius Regaud, Toulouse, France, and researchers at the Federation National des Centres de Lutte Contre le Cancer Women conducted a trial of 1999 women with operable, node-positive, early stage breast cancer.

      In this cohort, 993 women were randomized to receive 6 cycles of FEC 100 and 1,003 were assigned to 3 cycles of FEC 100 and then 3 cycles of docetaxel 100 mg/m2 on the first day of the cycle, with the cycles were repeated every 21 days.

      The FEC 100 regimen consisted of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 on the first day of the cycle and then repeating that regimen every 3 weeks.

      "We saw a 23% increase in 5-year overall survival using the FEC 100 plus docetaxel regimen," said Dr. Roché in an oral presentation here on December 10th at the 27th San Antonio Breast Cancer Symposium.

      The 5-year survival for patients taking the sequential treatment was 90.7% compared with 86.7% among patients taking 6 cycles of FEC (P =.017), Dr. Roché said. Patients receiving the sequential treatment achieved a disease-free survival rate of 78.3% in the sequential arm and 73.2% in the FEC100-only arm (P =.014), he said.

      "These results may provide additional hope for women with node-positive, early stage breast cancer," Dr. Roché said.

      "Women aged 50 years or older may particularly benefit from this regimen," he added. The finding that the benefit of the sequential treatment appeared to be better in older women than in younger women "came as a surprise to us," he said.

      Clifford Hudis, MD, chief, Breast Cancer Medicine Service, and associate attending physician, Memorial Sloan-Kettering Cancer Center, New York, New York, said, "I would be cautious about putting too much emphasis on the age differences. We have to be wary about the findings in subsets of patients, especially when those findings are not what we would expect."

      "I certainly wouldn't want anyone to withhold treatment with docetaxel from a young woman on the basis of this study," Dr. Hudis said.

      He said that the fewer cycles of epirubicin in the sequential treatment might also be helpful in preventing heart problems that often occur with anthracycline-based chemotherapy regimens.

      William Gradishar, MD, associate professor of medicine, Northwestern University Medical School, Chicago, Illinois, commented, "The study results reaffirm that epirubicin is an integral component of treatment of patients with node-positive breast cancer."

      The independent study received partial funding from Pharmacia Corporation, now part of Pfizer Inc., the marketer of epirubicin (Ellence) and by Sanofi-Aventis, which markets docetaxel (Taxotere).


      [Presentation title: Five Years Analysis of the PACS 01 trial: 6 Cycles of FEC100 Vs. 3 Cycles of FEC100 Followed by 3 Cycles of Docetaxel (D) for the Adjuvant Treatment of Node Positive Breast Cancer. Abstract 27]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send